Mark Schoenberg - Sep 9, 2024 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role: Chief Medical Officer
Signature: /s/ Jason D. Smith, Attorney-in-Fact
Stock symbol: URGN
Transactions as of: Sep 9, 2024
Transactions value $: -$11,236
Form type: 4
Date filed: 9/12/2024, 01:54 PM
Previous filing: Jun 11, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	URGN	Ordinary Shares	Options Exercise		+1.67K	+1.15%		146K	Sep 9, 2024	Direct	F1
transaction	URGN	Ordinary Shares	Sale	-$11.2K	-859	-0.59%	$13.08	145K	Sep 9, 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	URGN	Restricted Stock Units	Options Exercise	$0	-1.67K	-33.32%	$0.00	3.33K	Sep 9, 2024	Ordinary Shares	1.67K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2	Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3	The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.